Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
BackgroundConsidered a significant risk to health and survival, type 1 diabetes (T1D) is a heterogeneous autoimmune disease characterized by hyperglycemia caused by an absolute deficiency of insulin, which is mainly due to the immune-mediated destruction of pancreatic beta cells.Scope of reviewIn re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.1090842/full |
| _version_ | 1797956478050500608 |
|---|---|
| author | Jia-Tong Ding Jia-Tong Ding Kang-Ping Yang Kong-Lan Lin Yu-Ke Cao Fang Zou |
| author_facet | Jia-Tong Ding Jia-Tong Ding Kang-Ping Yang Kong-Lan Lin Yu-Ke Cao Fang Zou |
| author_sort | Jia-Tong Ding |
| collection | DOAJ |
| description | BackgroundConsidered a significant risk to health and survival, type 1 diabetes (T1D) is a heterogeneous autoimmune disease characterized by hyperglycemia caused by an absolute deficiency of insulin, which is mainly due to the immune-mediated destruction of pancreatic beta cells.Scope of reviewIn recent years, the role of immune checkpoints in the treatment of cancer has been increasingly recognized, but unfortunately, little attention has been paid to the significant role they play both in the development of secondary diabetes with immune checkpoint inhibitors and the treatment of T1D, such as cytotoxic T-lymphocyte antigen 4(CTLA-4), programmed cell death protein-1(PD-1), lymphocyte activation gene-3(LAG-3), programmed death ligand-1(PD-L1), and T-cell immunoglobulin mucin protein-3(TIM-3). Here, this review summarizes recent research on the role and mechanisms of diverse immune checkpoint molecules in mediating the development of T1D and their potential and theoretical basis for the prevention and treatment of diabetes.Major conclusionsImmune checkpoint inhibitors related diabetes, similar to T1D, are severe endocrine toxicity induced with immune checkpoint inhibitors. Interestingly, numerous treatment measures show excellent efficacy for T1D via regulating diverse immune checkpoint molecules, including co-inhibitory and co-stimulatory molecules. Thus, targeting immune checkpoint molecules may exhibit potential for T1D treatment and improve clinical outcomes. |
| first_indexed | 2024-04-10T23:50:24Z |
| format | Article |
| id | doaj.art-9355811ab6814cf2be69a31e4ab7832f |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-10T23:50:24Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-9355811ab6814cf2be69a31e4ab7832f2023-01-10T19:39:09ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-01-011310.3389/fendo.2022.10908421090842Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetesJia-Tong Ding0Jia-Tong Ding1Kang-Ping Yang2Kong-Lan Lin3Yu-Ke Cao4Fang Zou5Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaThe Second Clinical Medicine School, Nanchang University, Nanchang, ChinaThe Second Clinical Medicine School, Nanchang University, Nanchang, ChinaThe Second Clinical Medicine School, Nanchang University, Nanchang, ChinaSchool of Ophthalmology & Optometry, Nanchang University, Nanchang, ChinaDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaBackgroundConsidered a significant risk to health and survival, type 1 diabetes (T1D) is a heterogeneous autoimmune disease characterized by hyperglycemia caused by an absolute deficiency of insulin, which is mainly due to the immune-mediated destruction of pancreatic beta cells.Scope of reviewIn recent years, the role of immune checkpoints in the treatment of cancer has been increasingly recognized, but unfortunately, little attention has been paid to the significant role they play both in the development of secondary diabetes with immune checkpoint inhibitors and the treatment of T1D, such as cytotoxic T-lymphocyte antigen 4(CTLA-4), programmed cell death protein-1(PD-1), lymphocyte activation gene-3(LAG-3), programmed death ligand-1(PD-L1), and T-cell immunoglobulin mucin protein-3(TIM-3). Here, this review summarizes recent research on the role and mechanisms of diverse immune checkpoint molecules in mediating the development of T1D and their potential and theoretical basis for the prevention and treatment of diabetes.Major conclusionsImmune checkpoint inhibitors related diabetes, similar to T1D, are severe endocrine toxicity induced with immune checkpoint inhibitors. Interestingly, numerous treatment measures show excellent efficacy for T1D via regulating diverse immune checkpoint molecules, including co-inhibitory and co-stimulatory molecules. Thus, targeting immune checkpoint molecules may exhibit potential for T1D treatment and improve clinical outcomes.https://www.frontiersin.org/articles/10.3389/fendo.2022.1090842/fullimmune checkpointsimmune checkpoint inhibitorstype 1 diabeteslymphocyteimmunotherapy |
| spellingShingle | Jia-Tong Ding Jia-Tong Ding Kang-Ping Yang Kong-Lan Lin Yu-Ke Cao Fang Zou Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes Frontiers in Endocrinology immune checkpoints immune checkpoint inhibitors type 1 diabetes lymphocyte immunotherapy |
| title | Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes |
| title_full | Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes |
| title_fullStr | Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes |
| title_full_unstemmed | Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes |
| title_short | Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes |
| title_sort | mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes |
| topic | immune checkpoints immune checkpoint inhibitors type 1 diabetes lymphocyte immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.1090842/full |
| work_keys_str_mv | AT jiatongding mechanismsandtherapeuticstrategiesofimmunecheckpointmoleculesandregulatorsintype1diabetes AT jiatongding mechanismsandtherapeuticstrategiesofimmunecheckpointmoleculesandregulatorsintype1diabetes AT kangpingyang mechanismsandtherapeuticstrategiesofimmunecheckpointmoleculesandregulatorsintype1diabetes AT konglanlin mechanismsandtherapeuticstrategiesofimmunecheckpointmoleculesandregulatorsintype1diabetes AT yukecao mechanismsandtherapeuticstrategiesofimmunecheckpointmoleculesandregulatorsintype1diabetes AT fangzou mechanismsandtherapeuticstrategiesofimmunecheckpointmoleculesandregulatorsintype1diabetes |